1Current status of therapeutic plasmapheresis and related techniques. Re- port of the AMA panel on therapeutic plasmapheresis. Council on Scien- tific Affairs[J]. JAMA,1985,253(6):819 -825.
2Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice evidence - based approach from the Apheresis Applications Committee of the American Society for Apheresis[ J]. J Clin Apher ,2010 ,25 ( 3 ) :83 - 177.
3Wei N, Klippel JH, Huston DP, et al. Randomised trial of plasma ex- change in mild systemic lupus erythematosus [ J ]. Lancet, 1983, 1 (8314 -5) :17 -22.
4Wright EC, Tullus K, Dillon MJ. Retrospective study of plasma exchange in children with systemic lupus erythematosus [ J ]. Pediatr Nephrol, 2004,19(10) :1108 -1114.
5Zhang W, Shi H, Ren I-I, et al. Clinicopathological characteristics and out- come of Chinese patients with thrombotic thrombocytopenic purpura - he- molytic uremic syndrome : A 9 - year retrospective study [ J ]. Nephron Clin Pract,2009,112(3) :c177 - c183.
6Salant DJ. Intravenous methylprednisolone or plasma exchange for ad- junctive therapy of severe renal vasculitis [ J ]. Nat Clin Pract Nephrol, 2008,4(1) :14 -15.
7Johnson JP, Moore J Jr, Austin HA 3 rd, et al. Therapy of anti -glomeru- lar basement membrane antibody disease:Analysis of prognostic signifi- cance of clinical, pathologic and treatment factors [ J ]. Medicine ( Balti- more) ,1985,64(4) :219 -227.
8Seck SM,Bertrand D,Boucar D. Current indication of plasma exchanges in nephrology : A systematic review [ J ]. Saudi J Kidney Dis Transpl, 2011,22(2) :219 -224.
9Wright E, Dillon M J, Tullus K. Childhood vaseulitis and plasma ex- change [ J ]. Eur J Pediatr,2007,166 (2) : 145 - 151.
10Jennette-JC, Xiao H, Falt~ RJ. Pathogenesis of vascular inflammation by anti - neutrophil cytoplasmic antibodies [ J ]. J Am Soc Nephrol, 2006, 17(5) :1235 - 1242.
2Taylor CM, Chua C, Howie AJ, et al. Clinico-pathological findings in diarrhoea-negative haemolytic uraemic syndrome [J ]. Pediatr Nephrol,2004, 19(4):419-425.
3Zipfel PF, Skerka C. Complement dysfunction in hemolytic uremic syndrome[J]. Curr Opin Rheumatol, 2006,18(5):548-555.
4Dervenoulas J, Tsirigotis P, Bollas G, et al. Thrombotic thrombocytopenic purpura/Hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases[J]. Ann Hematol, 2000, 79(2):66-72.
5Oakes RS, Siegler RL, McReynolds MA, et al. Predictors of fatality in postdiarrheal hemolytic uremic syndrome [J ]. Pediatrics, 2006, 117(5):1656-1662.
6Garg AX, Salvadori M, Okell JM, et al. Albuminuria and estimated GFR 5 years after Escherichia Coli O157 hemolytic uremic syndrome: an updale [J], Am J Kidney Dis, 2008 , 51 (3) : 435-444.
8Choi BG,Yoo WH. Successful treatment of pure red cell aplasia with plasmapheresis in a patient with systemic lupus erythematosus. Yonsei Med J,2002,43 ( 1 ) :2-9.
9Naik B, Hirshhom S, Dharnidharka VR. Prolonged neuromuscular block due to eholinesterase depletion by plasmapheresis. Clin Anesth, 2002,14 ( 1 ) :5-16.
3JANKA G E. Familial and acquired hemophagocytic lymphohistio- cytosis [ J ]. Eur J Pediatr,2007,166 : 95 - 109.
4Kilic M ,Ozturk F,Gene G,et al. Sodium ni-tniprusside and toxic epidermal necrolysis[J]. Asian Pac J Allery Jmmunol ,2012 ,30(3):243 -245.
5Tiwari P, Panik R, Bhattacharya A, et al.Toxic epidermal necrolysis : an update [ J ].Asian Pae J Trop Dis,2013 ,3 (2) :85 -92.
6FerrancJiz-PuJido C,Garcia-Femdndez D,Donnnguez-Sampedro P,et al. Stevens-John-son syndrome and toxic epklerma] necrolysisin children : a review of the experience withpaediatric patients in a university hospital[J]. J Eur Acad Dermatol Veiiereol,2011,25( 10) :1153 -1159.
7Forman R, Koren G, Shear NH. Erythemamultiforme,Stevens-Johnson syndrome andtoxic epidermal necrolysis in children : a re-view1 of 10 years Experience [ J ]. Drug Saf,2002,25(13):965 -972.
9Mockenhaupt M, Norgauer J. Cutaneous ad- ve~e dn~g reactions: Stevens-Johnson syn- drome and toxic epideral necrolysis [ J ]. Al- lergy Clin Immnnol Int,2002,14 (4) : 143 - 150.
10Levi N , Bastuji-Garin S,Mockenhaupt M,etal. Medications as risk factors of Stevens-Johnson syndrome an toxic epidermal necrol-ysis in children:a pooled analysis[ J]. Pedi-atrics,2009,123(2) :e297 -304.
